These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8893121)

  • 1. A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.
    Hart SM; Bailey EM
    Ann Pharmacother; 1996 Oct; 30(10):1130-40. PubMed ID: 8893121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-lactam/β-lactamase inhibitor combinations: from then to now.
    Toussaint KA; Gallagher JC
    Ann Pharmacother; 2015 Jan; 49(1):86-98. PubMed ID: 25361682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections.
    Finegold SM
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S9-14; discussion S26-7. PubMed ID: 10526868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia.
    Ramirez JA
    Ann Pharmacother; 1998 Jan; 32(1):S22-6. PubMed ID: 9475836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.
    Wolff M; Joly-Guillou ML; Farinotti R; Carbon C
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1406-11. PubMed ID: 10348761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
    Prabhakaran K; Harris EB; Randhawa B; Adams LB; Williams DL; Hastings RC
    Microbios; 1993; 76(309):251-61. PubMed ID: 8302203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-lactam/beta-lactamase inhibitor combinations in empiric management of pediatric infections.
    Adam D
    J Int Med Res; 2002; 30 Suppl 1():10A-19A. PubMed ID: 11921490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
    Li C; Nicolau DP; Lister PD; Quintiliani R; Nightingale CH
    J Antimicrob Chemother; 2004 Feb; 53(2):297-304. PubMed ID: 14729755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains.
    Brauers J; Frank U; Kresken M; Rodloff AC; Seifert H
    Clin Microbiol Infect; 2005 Jan; 11(1):24-30. PubMed ID: 15649300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical role of beta-lactam/beta-lactamase inhibitor combinations.
    Lee N; Yuen KY; Kumana CR
    Drugs; 2003; 63(14):1511-24. PubMed ID: 12834367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection.
    Powell LL; Wilson SE
    Surg Infect (Larchmt); 2000; 1(1):57-63. PubMed ID: 12594910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital-acquired respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
    Akova M
    Int J Clin Pract Suppl; 2002 Mar; (125):19-27; discussion 37-9. PubMed ID: 12014853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lactam antibiotic and beta-lactamase inhibitor combinations.
    Lee NL; Yuen KY; Kumana CR
    JAMA; 2001 Jan 24-31; 285(4):386-8. PubMed ID: 11242403
    [No Abstract]   [Full Text] [Related]  

  • 18. [In vitro activity of beta-lactam agents and beta-lactamase inhibitors in clinical isolates of Acinetobacter baumannii].
    López-Hernández S; Alarcón T; Delgado T; de Las Cuevas MC; López-Brea M
    Rev Esp Quimioter; 1999 Jun; 12(2):140-3. PubMed ID: 10562675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI; Farooqi BJ
    J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New β-lactam-β-lactamase inhibitor combinations in clinical development.
    Shlaes DM
    Ann N Y Acad Sci; 2013 Jan; 1277():105-14. PubMed ID: 23346860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.